The pediatric adjunct study included a later behavioral assessment, which is different from simply measuring how quickly children woke up.
The open-label randomized study enrolled 256 children undergoing isolated plasma radiofrequency adenoidectomy. Three remimazolam infusion regimens were added to sevoflurane and compared with a saline control. Remimazolam groups had lower peak emergence-delirium scores and fewer negative behavioral changes reported on postoperative day three. Higher tested regimens also had lower pain scores and shorter recovery-unit stays, despite longer awakening times.
The children did not undergo tonsillectomy, so the procedure and pain burden should remain explicit. Lack of blinding can influence behavioral ratings and parental satisfaction. A day-three behavior measure does not establish long-term neurodevelopmental benefit, and apparent dose patterns require the actual between-group comparisons rather than selection of the most favorable result.
In a pediatric recovery review, separate immediate agitation, pain, family observations after discharge and longer-term cognitive outcomes. A calmer emergence does not automatically mean faster awakening, and parental satisfaction is not a direct neurological assessment. The paper helps show why outcome selection matters: several aspects of recovery moved in different directions under one regimen. It cannot retrospectively establish the cause of a child’s later behavior without the child’s baseline, illness, sleep and other treatment history.
Source: PMC12579177, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: A Pediatric Emergence Trial Lacked an Untreated Control.